Cellect Biotechnology (APOP) vs. Presbia (LENS) Critical Comparison

Cellect Biotechnology (NASDAQ: APOP) and Presbia (NASDAQ:LENS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Insider & Institutional Ownership

0.6% of Cellect Biotechnology shares are held by institutional investors. Comparatively, 15.5% of Presbia shares are held by institutional investors. 74.7% of Presbia shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Cellect Biotechnology has a beta of 4.59, meaning that its stock price is 359% more volatile than the S&P 500. Comparatively, Presbia has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Cellect Biotechnology and Presbia, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellect Biotechnology 0 0 1 0 3.00
Presbia 0 0 3 0 3.00

Cellect Biotechnology currently has a consensus price target of $14.00, suggesting a potential upside of 110.53%. Presbia has a consensus price target of $9.67, suggesting a potential upside of 313.11%. Given Presbia’s higher probable upside, analysts clearly believe Presbia is more favorable than Cellect Biotechnology.

Profitability

This table compares Cellect Biotechnology and Presbia’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cellect Biotechnology N/A -153.95% -92.92%
Presbia N/A -191.45% -145.39%

Valuation & Earnings

This table compares Cellect Biotechnology and Presbia’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cellect Biotechnology N/A N/A -$8.14 million ($1.46) -4.55
Presbia $10,000.00 4,006.08 -$16.99 million ($1.18) -1.98

Cellect Biotechnology has higher earnings, but lower revenue than Presbia. Cellect Biotechnology is trading at a lower price-to-earnings ratio than Presbia, indicating that it is currently the more affordable of the two stocks.

Summary

Presbia beats Cellect Biotechnology on 7 of the 11 factors compared between the two stocks.

Cellect Biotechnology Company Profile

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company was founded in 2011 and is headquartered in Kfar Saba, Israel.

Presbia Company Profile

Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company provides the refractive lens for patient surgeries, as well as accessories for procedures. It primarily operates in South Korea, Australia, the Netherlands, Ireland, and Canada. The company was founded in 2014 and is headquartered in Dublin, Ireland.

Receive News & Ratings for Cellect Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellect Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply